by Matthew Perrone
Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains.
The Food and Drug Administration holds a two-day meeting starting Monday to examine the latest research on anti-inflammatory medicines called NSAIDS, which serve as the backbone of U.S. pain treatment.
The key question is whether naproxen—the key ingredient in Bayer's Aleve and many other generic pain pills—carries a lower risk of heart attack and stroke than rival medications like ibuprofen, sold as Advil by Pfizer, among others.
Debate about whether one drug is safer than the others has waged for more than a decade without a clear answer.
Explore further: FDA: Aleve may be safer on heart than rival drugs
© 2014 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
FDA: Aleve may be safer on heart than rival drugs
Jan 28, 2014
Federal health experts say the pain reliever found in Aleve may be safer on the heart than other popular anti-inflammatory drugs taken by millions of Americans.
Red flags on pain reliever safety
Jul 19, 2011
For many people, pain relievers are wonder drugs, allowing them to carry on with their lives despite disabling arthritis, for instance, or recurrent headaches. But all pain relievers, whether sold over-the counter (OTC) or ...
Daily aspirin may guard against ovarian cancer
Feb 06, 2014
(HealthDay)—Taking aspirin every day might lower a woman's risk of developing ovarian cancer by one-fifth, a new study suggests.
Osteoarthritis medicine delivered on-demand
Nov 06, 2013
Scientists are reporting development of a squishy gel that when compressed—like at a painful knee joint—releases anti-inflammatory medicine. The new material could someday deliver medications when and where osteoarthritis ...
FDA links once-promising pain drugs to bone decay
Mar 08, 2012
Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.
Recommended for you
Teva says US is investigating Copaxone marketing
1 hour ago
Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.
Pharma data play larger role in anti-doping effort
Feb 07, 2014
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.
Physicians need to be prepared to talk antibiotics
Feb 07, 2014
(HealthDay)—Patient pressure to receive antibiotic prescriptions remains a challenge for providers who are trying to combat antibiotic resistance by curbing prescriptions for viral infections, according ...
Sanofi earns soar on lower restructuring costs (Update)
Feb 06, 2014
French drug maker Sanofi said Thursday its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments.
NY authorities say $170M pill ring shut down
Feb 05, 2014
Authorities say they've shut down several New York City medical clinics and arrested two dozen people in a scheme to sell more than 5 million prescription painkillers on the black market.
Indian drug giant Ranbaxy trims losses but future is bleaker
Feb 05, 2014
Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment